Trial Profile

A Phase 1/2 Study of BA3071 in Patients With Solid Tumors

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 24 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs BA 3071 (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary)
Indications Malignant melanoma; Non-small cell lung cancer; Solid tumours
Focus Adverse reactions; Therapeutic Use
Sponsors BioAtla

Most Recent Events

15 Jun 2025 Status changed from recruiting to active, no longer recruiting.
06 May 2025 According to a BioAtla media release, Phase 1 and phase 2 data read-outs are ongoing across solid tumor types (median of 3 prior lines of treatment).
27 Mar 2025 According to a BioAtla media release, company initiated partnering discussions Q1 2025.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com